Please select the option that best describes you:
In patients with metastatic hormone receptor positive breast cancer who have received CDK 4/6 inhibitor either in the adjuvant setting or past line of therapy after metastatic progression, is there any data to support CDK 4/6 inhibitor retreatment?
For example if a patient progresses on adjuvant CDK 4/6 inhibitor as given per MonarchE would there be any consideration for its use later in the metastatic setting